Multi-modal weight control intervention for people with persistent mental disorders

Psychiatric Rehabilitation Journal

Volumn 31, Issue 3, 2008, Pages 194-200

  Melamed, Yuval ^a,b   Stein Reisner, Orit ^a,b   Gelkopf, Marc ^a   Levi, Galit ^a   Sivan, Tami ^a   Ilievici, Gloria ^a   Rosenberg, Ruth ^a   Weizman, Abraham ^b   Bleich, Avi ^a,b  

^a LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Body mass index; Obesity; Schizophrenia; Weightless

Indexed keywords

ADULT; ARTICLE; BODY MASS; CHI SQUARE TEST; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXERCISE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; NUTRITION; OBESITY; QUALITY OF LIFE; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; WEIGHT CONTROL; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; BEHAVIOR THERAPY; COMORBIDITY; DIET; FOLLOW UP; HEALTH EDUCATION; ISRAEL; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

ANALYSIS OF VARIANCE; BEHAVIOR THERAPY; BODY MASS INDEX; COMORBIDITY; DIET; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEALTH EDUCATION; HUMANS; ISRAEL; MALE; MENTAL DISORDERS; MIDDLE AGED; NUTRITION PHYSIOLOGY; OBESITY; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; WEIGHT LOSS;

EID: 42949140975     PISSN: 1095158X     EISSN: None     Source Type: Journal    
DOI: 10.2975/31.3.2008.194.200     Document Type: Article

References (32)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
2. Archie, S., Wilson, J. H., Osborne, S., Hobbs, H., & McNiven, J. (2003). Pilot study: Access to fitness facility and exercise levels in olanzapine-treated patients. Canadian Journal of Psychiatry 48, 628-632.
3. Aronne, L. J. (2001). Epidemiology, morbidity, and treatment of overweight and obesity. Journal of Clinical Psychiatry 62, Suppl 23, 13-22.
4. Ball, M. P., Coons, V. B., & Buchanan, R. W. (2001). A program for treating olanzapine-related weight gain. Psychiatric Services 52, 967-969.
5. Brar, J. S., Ganguli, R., Pandina, G., Turkoz, I., Berry, S., & Mahmoud, R. (2005). Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 66, 205-612.
6. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. (2004). Diabetes Care 27, 596-601.
7. Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin 29, 321-326.
8. Faulkner, G., & Cohn, T. A. (2006). Pharmacologic and non-pharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Canadian Journal of Psychiatry 51, 502-511.
9. Faulkner, G., Soundy, A. A., & Lloyd, K. (2003). Schizophrenia and weight gain management: A systematic review of interventions to control weight. Acta Psychiatrica Scandinavica 108, 324-332.
10. Ganguli, R. (1999). Weight gain associated with antipsychotic drugs. Journal of Clinical Psychiatry 60, Suppl 21, 20-24.
11. Greenberg, I., Chan, S., & Blackburn, G. L. (1999). Nonpharmacologic and pharmacologic management of weight gain. Journal of Clinical Psychiatry 60, Suppl 21, 31-36.
12. Haddad, P. (2005). Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of Psychopharmacology 19(6 Suppl), 16-27.
13. Kalarchian, M. A., Marcus, M. D., Levine, M. D., Haas, G. L., Greeno, C. G., Weissfeld, L. A., & Qin, L. (2005). Behavioral treatment of obesity in patients taking antipsychotic medications. Journal of Clinical Psychiatry 66, 1058-1063.
14. Kawachi, I. (1999). Physical and psychological consequences of weight gain. Journal of Clinical Psychiatry 60, Suppl 21, 5-9.
15. Kay, S. R., Fiszbein, A., Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
16. Knolle-Veentjer, S., Huth, V., Ferstl, R., Aldenhoff, J. B., & Hinze-Selch, D. (2006). Delay of gratification and executive performance in individuals with schizophrenia: Putative role for eating behavior and body weight regulation. Journal of Psychiatric Research, Nov 23; [Epub ahead of print].
17. Koga, M., & Nakayama, K. (2005). Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatrica Scandinavica 112, 75-76; discussion 77.
18. Kurzthaler, I., Fleischhacker, W. W. (2001). The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry 62, Suppl 7, 32-37.
19. Kwon, J. S., Choi, J. S., Bahk, W. M., Yoon Kim, C., Hyung Kim, C., Chul Shin, Y., Park, B. J., & Geun Oh, C. (2006). Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry 67, 547-553.
20. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
21. Lu, M. L., Lane, H. Y., Lin, S. K., Chen, K.P., & Chang, W. H. (2004). Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Journal of Clinical Psychiatry 65, 766-771.
22. McIntyre, R. S., Mancini, D. A., & Basile, V. S. (2001). Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 62, Suppl 23, 23-29.
23. Menza, M., Vreeland, B., Minsky, S., Gara, M., Radler, D. R., & Sakowitz, M. (2004). Managing atypical antipsychotic-associated weight gain: 12-month data on a multi-modal weight control program. Journal of Clinical Psychiatry 65, 471-477.
24. O'Keefe, C. D., Noordsy, D. L., Liss, T. B., & Weiss, H. (2003). Reversal of antipsychotic-associated weight gain. Journal of Clinical Psychiatry 64, 907-912.
25. Peet, M. (2004). Diet, diabetes and schizophrenia: Review and hypothesis. British Journal of Psychiatry 184, Suppl 47, 102-105.
26. Poyurovsky, M., Isaacs, I., Fuchs, C., Schneidman, M., Faragian, S., Weizman, R., & Weizman, A. (2003). Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. American Journal of Psychiatry 60, 297-302.
27. Poyurovsky, M., Pashinian, A., Gil-Ad, I., Maayan, R., Schneidman, M., Fuchs, C., & Weizman, A. (2002). Olanzapine-induced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry. 159, 1058-1060.
28. Poyurovsky, M., Pashinian, A., Levi, A., Weizman, R., & Weizman, A. (2005). The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. International Clinical Psychopharmacology 20, 101-103.
29. Tsai, A. G., & Wadden, T. A. (2005). Systematic review. An evaluation of major commercial weight loss programs in the United States. Annals of Internal Medicine 142, 56-66.
30. Umbricht, D., Flury, H., & Bridler, R. (2001). Cognitive behavior therapy for weight gain. American Journal of Psychiatry 158, 971.
31. Vreeland, B., Minsky, S., Menza, M., Rigassio-Radler, D., Roemheld-Hamm, B., & Stern, R. A. (2003). Program for managing weight gain associated with atypical antipsychotics. Psychiatric Services 54, 1155-1157.
32. Weber, M., & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research 83, 95-101.